Literature DB >> 2007852

The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain.

M H Tao1, S M Canfield, S L Morrison.   

Abstract

Using domain switch chimeric antibodies, we confirm the important role of CH2 in complement activation. In addition, we demonstrate that the structures responsible for the differential ability of human IgG1 and IgG4 to activate complement are located at the COOH-terminal part (from residue 292 to 340) of the CH2 domain. The amino acids in CH2 that might be involved in complement interaction are discussed. While CH3 contributes to efficient complement activation, CH3 from IgG2 and CH3 IgG3 are equally effective.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007852      PMCID: PMC2190803          DOI: 10.1084/jem.173.4.1025

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  14 in total

1.  Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins.

Authors:  L K Tan; R J Shopes; V T Oi; S L Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

2.  Production and properties of chimeric antibody molecules.

Authors:  S U Shin; S L Morrison
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

3.  The structure and function of immunoglobulin domains. IV. The distribution of some effector functions among the Cgamma2 and Cgamma3 homology regions of human immunoglobulin G1.

Authors:  D Yasmeen; J R Ellerson; K J Dorrington; R H Painter
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

Review 4.  Structure and function of the constant regions of immunoglobulins.

Authors:  D Beale; A Feinstein
Journal:  Q Rev Biophys       Date:  1976-05       Impact factor: 5.318

5.  Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor.

Authors:  R J Leatherbarrow; T W Rademacher; R A Dwek; J M Woof; A Clark; D R Burton; N Richardson; A Feinstein
Journal:  Mol Immunol       Date:  1985-04       Impact factor: 4.407

6.  Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution.

Authors:  J Deisenhofer
Journal:  Biochemistry       Date:  1981-04-28       Impact factor: 3.162

7.  Characterization of a plasmin-digest fragment of rabbit immunoglobulin gamma that binds antigen and complement.

Authors:  M Colomb; R R Porter
Journal:  Biochem J       Date:  1975-02       Impact factor: 3.857

8.  Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.

Authors:  M H Tao; S L Morrison
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

9.  Preparation and biologic characterization of fragments containing dimeric and monomeric C gamma 2 domain of rabbit IgG.

Authors:  S Utsumi; M Okada; K Udaka; T Amano
Journal:  Mol Immunol       Date:  1985-07       Impact factor: 4.407

10.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

Authors:  M Brüggemann; G T Williams; C I Bindon; M R Clark; M R Walker; R Jefferis; H Waldmann; M S Neuberger
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  33 in total

Review 1.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

2.  IgG2m4, an engineered antibody isotype with reduced Fc function.

Authors:  Zhiqiang An; Gail Forrest; Renee Moore; Michael Cukan; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jing Zhang Zhao; Ping Lu; Jin Hua; Christopher R Gibson; Barrett R Harvey; Donna Montgomery; Dennis Zaller; Fubao Wang; William Strohl
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

3.  IgG4 production against adalimumab during long term treatment of RA patients.

Authors:  Pauline A van Schouwenburg; Charlotte L Krieckaert; Michael Nurmohamed; Margreet Hart; Theo Rispens; Lucien Aarden; Diana Wouters; Gerrit Jan Wolbink
Journal:  J Clin Immunol       Date:  2012-05-24       Impact factor: 8.317

4.  The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.

Authors:  A Morgan; N D Jones; A M Nesbitt; L Chaplin; M W Bodmer; J S Emtage
Journal:  Immunology       Date:  1995-10       Impact factor: 7.397

5.  An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

Authors:  Oskar Adolfsson; Maria Pihlgren; Nicolas Toni; Yvan Varisco; Anna Lucia Buccarello; Katia Antoniello; Sophie Lohmann; Kasia Piorkowska; Valerie Gafner; Jasvinder K Atwal; Janice Maloney; Mark Chen; Alvin Gogineni; Robby M Weimer; Deborah L Mortensen; Michel Friesenhahn; Carole Ho; Robert Paul; Andrea Pfeifer; Andreas Muhs; Ryan J Watts
Journal:  J Neurosci       Date:  2012-07-11       Impact factor: 6.167

6.  Influence of IgG Subclass on Human Antimannan Antibody-Mediated Resistance to Hematogenously Disseminated Candidiasis in Mice.

Authors:  Casey T Nishiya; Gayle M Boxx; Kerry Robison; Carol Itatani; Thomas R Kozel; Mason X Zhang
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

7.  Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Authors:  Kham R Trinh; Alex Vasuthasawat; Kristopher K Steward; Reiko E Yamada; John M Timmerman; Sherie L Morrison
Journal:  J Immunother       Date:  2013-06       Impact factor: 4.456

8.  Homogeneous immunoconjugates for boron neutron-capture therapy: design, synthesis, and preliminary characterization.

Authors:  L Guan; L A Wims; R R Kane; M B Smuckler; S L Morrison; M F Hawthorne
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 9.  Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions.

Authors:  Connie M Arthur; Satheesh Chonat; Ross Fasano; Marianne E M Yee; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Transfus Med Rev       Date:  2019-10-18

10.  A single residue switch reveals principles of antibody domain integrity.

Authors:  Benedikt Weber; Matthias J Brandl; María Daniela Pulido Cendales; Carolin Berner; Tejaswini Pradhan; Gina Maria Feind; Martin Zacharias; Bernd Reif; Johannes Buchner
Journal:  J Biol Chem       Date:  2018-09-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.